The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.
about
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry diseaseUnderstanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosisPain management strategies for neuropathic pain in Fabry disease--a systematic reviewLife expectancy and cause of death in males and females with Fabry disease: findings from the Fabry RegistryNeuropathic and cerebrovascular correlates of hearing loss in Fabry diseaseHome infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative groupCryptogenic stroke and small fiber neuropathy of unknown etiology in patients with alpha-galactosidase A -10T genotype.Enzyme replacement therapy for Fabry disease: some answers but more questionsCharacterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.A Retrospective Survey Studying the Impact of Fabry Disease on Pregnancy.Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.Paediatric Fabry disease: prognostic significance of ocular changes for disease severity.Agalsidase benefits renal histology in young patients with Fabry disease.Gastrointestinal Symptoms of Patients with Fabry Disease.Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease.A survey of the pain experienced by males and females with Fabry diseaseAssessment of renal pathology and dysfunction in children with Fabry disease.Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.Early therapeutic intervention in females with Fabry disease?Early cardiac changes in children with anderson-fabry disease.Fabry disease in children and the effects of enzyme replacement treatment.Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.Chronic intestinal pseudo-obstruction. Did you search for lysosomal storage diseases?Fabry disease: a review of current management strategies.Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.Safety of agalsidase alfa in patients with Fabry disease under 7 years.Fabry disease in infancy and early childhood: a systematic literature review.Perspectives in Pediatric Pathology, Chapter 21. Testicular Pathology in Heritable Metabolic Disease.Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review.Fabry disease in children: a federal screening programme in Russia.Early diagnosis of fabry disease in a patient with toe tip pain.Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.Cardiac manifestations of Anderson-Fabry disease in children and adolescents.Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.Therapeutic goals in the treatment of Fabry disease.Immunofluorescence detection of globotriaosylceramide deposits in conjunctival biopsies of Fabry disease patients.Modelling the resource implications of managing adults with Fabry disease in Italy.The relation between small nerve fibre function, age, disease severity and pain in Fabry disease.A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease.
P2860
Q24650910-70B2450A-9338-40EC-A267-34E2EB621152Q26745698-05BF2382-D380-4292-A839-44F22068D1D2Q26766561-9FEED876-C68F-4BF6-8438-2E7B9F1914C3Q28258153-2FFD65AB-505F-4043-A578-C3BAFFAE671BQ30501578-C7102E9F-1120-41BA-9B45-7C84FF314393Q33835524-33E92A65-8A7B-4ABF-B47B-CE7B2C45C226Q34632438-78A2B90E-BA0C-4AEE-B39E-7C7016B3D97AQ34703815-E0CD77A2-56A6-4D2A-B658-C3A8AFC00B15Q35587768-E31266EC-7F73-46EE-B3DF-9AFAA1EF0B3FQ35752504-1C19509F-AB57-4457-AC6E-849ED9F1B244Q35994824-DFADCE6D-8666-4D0F-83EA-693DB0EF2CB2Q36194571-A65E551E-9849-41DC-8729-85CFE931E5BBQ36509288-0552B372-6824-4CA0-9970-9C27A8B72BE2Q36529707-7F8016E1-6D44-484D-A3E4-5B886D81966DQ36596408-C8909F31-4100-456B-AD6F-FDC28ADB438CQ36854195-1F4DE212-73FD-4454-9254-6AC708E57393Q36883412-12F5DED5-A1C5-403D-BC08-F2113E32640DQ37007821-EA47F048-5A34-417D-B889-4B8ECA7FB812Q37109593-17C4BB9A-8E67-49E5-8F1D-C49473BB7C2CQ37109597-AA3CF1F5-701D-456D-9FC8-8D37833B4611Q37127636-CE53C41A-E282-421D-A19A-B5A62D42B1A2Q37350401-FE05351E-CAF5-41EB-91B9-5AA1C41F5C05Q37352268-4803DCF7-527D-4C93-966E-AAA9B1F61B5BQ37725235-B6A83794-49CF-4767-82F2-6503E6140431Q37775790-473D76A5-32C1-4285-9EB7-CB262A077D46Q37801828-F0160F90-3BF2-4BA7-8459-95A074D29BC5Q37813149-3045BDEF-3D8A-4ED3-9DE0-D76A25435E02Q38252008-5CA58859-BFA4-4919-900F-592D9D0FB7A8Q38264149-73871656-F33E-45EB-BF97-EAEAE9D7FC99Q38354004-42CB0537-010B-4AED-86E0-7422FCAB35BBQ42066201-2F436219-9FF2-49FC-AB27-834ED56C3FD8Q42429589-D3EE1087-E2F7-4D1D-A043-67B8A36F862DQ45118891-6ADC1F7D-BB03-4EB5-AC54-2C3242D2D2EBQ46684439-1BE95926-8ED3-4030-83AD-8C518E1AFC2BQ46735411-F0C644C7-0B65-4337-9CC1-F6CF78C8A6CAQ50436079-443790F3-0F4D-4C18-82DB-5FAAECA56C6BQ50715506-035DB323-1032-4D45-904E-77E98C8D4A26Q51158499-41F6F066-8271-4E88-BA4A-BF3F95273309Q51502505-5621490A-8C89-443E-94D6-130EE19FF284Q51646061-A4B8B885-1C6A-42F8-BEF3-77E34CBA6CCA
P2860
The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
The early clinical phenotype o ...... pean children and adolescents.
@en
The early clinical phenotype o ...... pean children and adolescents.
@nl
type
label
The early clinical phenotype o ...... pean children and adolescents.
@en
The early clinical phenotype o ...... pean children and adolescents.
@nl
prefLabel
The early clinical phenotype o ...... pean children and adolescents.
@en
The early clinical phenotype o ...... pean children and adolescents.
@nl
P2093
P1476
The early clinical phenotype o ...... opean children and adolescents
@en
P2093
Andreas Gal
Bengt Lindblad
Catharina Whybra
Ingrid Willers
Michael Beck
Uma Ramaswami
P2888
P304
P356
10.1007/S00431-003-1299-3
P577
2003-09-20T00:00:00Z